The role of comparative effectiveness research in transfusion medicine clinical trials: Proceedings of a National Heart, Lung, and Blood Institute workshop

Transfusion

Volumn 52, Issue 6, 2012, Pages 1363-1378

  Blajchman, Morris A ^{a,b,c,d,e,f,g,h}   Carson, Jeffrey L ^{a,b,c,d,e,f,g,h}   Eikelboom, JohnW ^{a,b,c,d,e,f,g,h}   Heddle, Nancy M ^{a,b,c,d,e,f,g,h}   Lacroix, Jacques ^{a,b,c,d,e,f,g,h}   Lauer, Michael S ^{a,b,c,d,e,f,g,h}   Platt, Richard ^{a,b,c,d,e,f,g,h}   Tilley, Barbara ^{a,b,c,d,e,f,g,h}   Triulzi, Darrell ^{a,b,c,d,e,f,g,h}   Vickers, Andrew J ^{a,b,c,d,e,f,g,h}   Yusuf, Salim ^{a,b,c,d,e,f,g,h}   Glynn, Simone ^{a,b,c,d,e,f,g,h}   Mondoro, Traci Heath ^{a,b,c,d,e,f,g,h}   Wagner, Elizabeth ^{a,b,c,d,e,f,g,h}  

^a MCMASTER UNIVERSITY   (Canada)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^g INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD STORAGE; BLOOD TRANSFUSION; CANADA; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; ERYTHROCYTE TRANSFUSION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART; HEMOSTASIS; HUMAN; LUNG; MEDICAL DECISION MAKING; MULTIPLE ORGAN FAILURE; NATIONAL HEALTH ORGANIZATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TRAINING;

AGE FACTORS; ALGORITHMS; BLOOD TRANSFUSION; CANADA; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; CONGRESSES AS TOPIC; HUMANS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); REGENERATIVE MEDICINE; TIME FACTORS; UNITED STATES;

EID: 84862268420     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03640.x     Document Type: Conference Paper

References (51)

1. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH; State-of-the Science Symposium Transfusion Medicine Committee. Clinical trial opportunities in transfusion medicine: proceedings of an NHLBI state-of-the-science symposium. Transfus Med Rev 2010;24:259-85.
2. Josephson CD, Glynn SA, Kleinman SH, Blajchman MA. A multi-disciplinary "Think Tank": the top 10 clinical trial opportunities in transfusion medicine from the NHLBI sponsored 2009 State-of-the-Science Symposium. Transfusion 2011;51:828-41.
3. Red Cell Storage Duration Study (RECESS). 2009. [cited 2012 Mar 15]. Available from: URL: http://www.clinicaltrials.gov/ct2/show/NCT00991341?term= NCT00991341&rank=1
4. Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People with Neutropenia (The RING Study). 2008. [cited 2012 Mar 15]. Available from: URL: http://www.clinicaltrials.gov/ct2/show/NCT00627393? term=NCT00627393&rank=1
5. Initial Treatment of Patients with Immune Thrombocytopenic Purpura (ITP2). 2009. [cited 2012 Mar 15]. Available from: URL: http://www. clinicaltrials.gov/ct2/show/NCT00991939?term=NCT00991939&rank=1
6. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Eng J Med 2008;358:1229-39. (Pubitemid 351439224)
7. Red Cell Storage Duration and Outcomes in Cardiac Surgery. 2007. [cited 2012 Mar 15]. Available from: URL: http://www.clinicaltrials.gov/ct2/results? term=NCT00458783
8. Lacroix J, Hébert PC, Fergusson D, Tinmouth A, Blajchman MA, Callum J, Cook D, Marshall JC, McIntyre L, Turgeon AF; ABLE study group. The age of blood evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev 2011;25:197-205.
9. Tinmouth A, Fergusson D, Chin-Yee I, Hebert PC. Clinical consequences of red cell storage in the critically ill. Transfusion 2006;46:2014-27. (Pubitemid 44631611)
10. Lacroix J, Tucci M. Impact clinique de la durée d'entreposage des globules rouges avant transfusion. Transf Clin Biol 2011;18:97-105.
11. Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion 2009;49:1384-94.
12. Hébert PC, Chin-Yee I, Fergusson D, Blajchman M, Martineau R, Clinch J, Olberg G. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg 2005;100:1433-8. (Pubitemid 40577401)
13. Maclure M. Explaining pragmatic trials to pragmatic policy-makers. CMAJ 2009;180:1001-3.
14. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 2009;180:E47-E57.
15. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council, Social Sciences and Humanities Research Council of Canada. Tri-council policy statement: ethical conduct for research involving humans. 2010. [cited 2011 Feb 21]. Available from: URL: http://www.pre.ethics.gc.ca/eng/ policy-politique/initiatives/tcps2-eptc2/Default/
16. Fergusson D, Hutton B, Hogan DL, LeBel L, Blajchman MA, Ford JC, Hebert P, Kakadekar A, Kovacs L, Lee S, Sankaran K, Shapiro S, Smyth JA, Ramesh K, Bouali NR, Tinmouth A, Walker R. The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design. Transfus Med Rev 2009;23:55-61.
17. Heddle NM, Cook RJ, Arnold DM, Crowther MA,Warkentin TE,Webert KE, Hirsh J, Barty RL, Liu Y, Lester C, Eikelboom JW. The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion 2012;52:1203-12.
18. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-62.
19. Milne I, Chalmers I. A controlled clinical trial in 1809? J Epidemiol Community Health 2002;56:1.
20. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43. (Pubitemid 23163355)
21. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women in high-risk primary breast cancer: a report of CALGB 9083, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-200. (Pubitemid 46222235)
22. Lauer MS, Collins FS. Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 2010;303:2182-3.
23. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: methods development, policy context and research infrastructure. Stat Med 2010;372:1963-76.
24. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making. JAMA 2003;290:1624-32. (Pubitemid 37430387)
25. Dorée C, Stanworth S, Brunskill SJ, Hopewell S, Hyde CJ, Murphy MF. Where are the systematic reviews in transfusion medicine? A study of the transfusion evidence base. Transfus Med Rev 2010;24:286-94.
26. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R. The cost effectiveness of preoperative autologous blood donations. N Engl JMed 1995;332:719-24.
27. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009;23:1-12.
28. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, Gonzalez EA, Pomper GJ, Perkins JG, Spinella PC, Williams KL, Park MS. Increased plasma and platelet to red blood cells ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008;248:447-58.
29. Cotton BA, Gunter OL, Isbell J, Au BK, Robertson AM, Morris JA Jr, St Jacques P, Young PP. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008;64:1177-82. (Pubitemid 351671208)
30. Duchesne JC, Hunt JP, Wahl G, Marr AB, Wang YZ, Weintraub SE, Wright MJ, McSwain NE Jr. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma 2008;65:272-6; discussion 276-8.
31. Kashuk JL, Moore EE, Johnson JL, Haenel J, Wilson M, Moore JB, Cothren CC, Biffl WL, Banerjee A, Sauaia A. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma : packed red blood cells the answer? J Trauma 2008;65:261-70.
32. Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J, Rosengart MR, Maier RV, Billiar TR, Peitzman AB, Moore EE; Inflammation the Host Response to Injury Investigators. An FPP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008;65:986-93.
33. Perkins JG, Cap AP, Spinella PC, Blackbourne LH, Grathwohl KW, Repine TB, Ketchum L, Waterman P, Lee RE, Beekley AC, Sebesta JA, Shorr AF, Wade CE, Holcomb JB. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. J Trauma 2009;66(Suppl):S77- S84.
34. Guice KS, Cassidy LD, Mann NC. State trauma registries: survey and update - 2004. J Trauma 2007;62:424-35.
35. Rahbar MH, Fox EE, Del Junco DJ, Cotton BA, Podbielski JM, Matijevic N, Cohen MJ, Schreiber MA, Zhang J, Mirhaji P, Duran SJ, Reynolds RJ, Benjamin-Garner R; Holcomb JB; The PROMMTT Investigators. Coordination and management of multicenter clinical studies in trauma: experience from the PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study. Resuscitation 2012;83:459-64.
36. Snyder CW, Weinberg JA, McGwin G Jr, Melton SM, George RL, Reiff DA, Cross JM, Hubbard-Brown J, Rue LW 3rd, Kerby JD. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 2009;66:358-62.
37. Ho AM, Dion PW, Yeung JH, Holcomb JB, Critchley LA, Ng CS, Karmakar MK, Cheung CW, Rainer TH. Prevalence of survivor bias in observational studies on fresh frozen plasma: erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012;116:716-28.
38. Merkow RP, Ko CY. Evidence-based medicine in surgery: the importance of both experimental and observational study designs. JAMA 2011;306:436-7.
39. Ware JH, Hamel MB. Pragmatic trials: guides to better patient care? N Engl J Med 2011;364:1685-7.
40. Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN; ACCORD Study Group. Rationale and design for the blood pressure intervention of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007;99:44i-55i.
41. Wright JT Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE; ALLHAT Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT): clinical center recruitment experience. Control Clin Trials 2001;22:659-73. (Pubitemid 33153034)
42. Platt R, Takvorian SU, Septimus E, Hickok J,Moody J, Perlin J, Jernigan JA, Kleinman K, Huang SS. Cluster randomized trials in comparative effectiveness research: randomizing hospitals to test methods for prevention of healthcare-associated infections.Med Care 2010;48:S52-S57.
43. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Statist Med 1984;3:409-22.
44. Francis T Jr. Evaluation of the 1954 poliomyelitis vaccine field trial; further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis. J Am Med Assoc 1955;158:1266-70.
45. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009;6:239-51.
46. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the actual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
47. Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS,McGuire S,Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL; Case of Cancer and Leukemia Group B. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the case of cancer and leukemia group B. J Clin Oncol 2006;24:4553-7. (Pubitemid 46630950)
48. Vickers AJ. Do we want more cancer patients on clinical trials. If so, what are the barriers to greater accrual. Trials 2008;9:31.
49. Lei Y, Alemozaffar M, Williams SB, Hevelone N, Lipsitz SR, Plaster BA, Amarasekera CA, Ulmer WD, Huang AC, Kowalczyk KJ, Hu JC. Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol 2011;59:235-42.
50. Vickers AJ, Scardino PT. The clinically-integrated randomized trial: proposed novel method for conducting large rials at low cost. Trials 2009;10:14.
51. Vickers AJ, Savage CJ, Shouery M, Eastham JA, Scardino P, Basch EM. Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health Qual Life Outcomes 2010;8:82.